# Third Quarter Fiscal 2014 Earnings

**Q**UALCOMM®



#### Safe harbor

This presentation and the conference call it accompanies contain forward-looking statements that are inherently subject to risks and uncertainties, including but not limited to statements regarding our business and financial outlook, including our lower near-term financial outlook for the licensing business and better than expected performance in our semiconductor business; demand for our 3G and multimode 3G/4G chipsets; the rollout and growth of 3G/LTE; challenges in China -including the NDRC investigation, a dispute with a licensee, suspected underreporting of 3G/4G device sales by certain licensees, and sales of unlicensed devices and the need to sign license agreements with certain OEMs -- our efforts and expectations regarding the resolution of these challenges and the timing thereof, as well as the potential impact on our business and financial results; our expectations regarding collecting royalties on LTE devices globally; our launch of new products; the launch of third party products based on our technologies; new business initiatives and opportunities; our Mirasol display technology and QMT division; and our estimates and guidance related to revenues, diluted earnings per share, MSM chip shipments, total reported device sales, 3G/4G channel inventory, 3G/4G device demand, 3G/4G device average selling prices, 3G/4G device shipments, operating margins, R&D and SG&A expenses and investment income. Forward-looking statements are generally identified by words such as "estimates," "guidance," "expects," "anticipates," "intends," "plans," "believes," "seeks" and similar expressions. Actual results may differ materially from those referred to in the forward-looking statements due to a number of important factors, including but not limited to: risks associated with the commercial deployment of CDMA, OFDMA and other technologies; continuing growth in our customers' and licensees' sales of products and services based on these technologies and our ability to continue to drive customer demand for our products and services based on these technologies; competition; our dependence on a small number of customers and licensees; the continued and future success of our licensing programs; attacks on our licensing business model, including current and future legal proceedings or actions of governmental or quasi-governmental bodies or standards or industry organizations; the enforcement and protection of our intellectual property rights; the commercial success of our new technologies, products and services; claims by third parties that we infringe their intellectual property; our dependence on a limited number of third-party suppliers; our stock price and earnings volatility; government regulations and policies; strategic transactions and investments; and global economic conditions that impact the mobile communications industry. These and other risks are set forth in our most recent Form 10-Q filed with the SEC, copies of which are available on our website at www.qualcomm.com. We undertake no obligation to update any forwardlooking statements.


This presentation includes a discussion of "non-GAAP financial measures" as that term is defined in Regulation G. The most directly comparable GAAP financial measures and information reconciling these non-GAAP financial measures to the Company's financial results prepared in accordance with GAAP are included at the end of this presentation.

## Qualcomm reports third quarter fiscal 2014 earnings

#### Third quarter ended June 29, 2014

- We are pleased to report another record quarter with revenues, earnings per share and chip shipments reaching all-time highs, driven by broad-based demand for our industry-leading 3G/4G chipset solutions.
- Looking forward, although we have lowered our near-term financial outlook for the licensing business, we are pleased to be raising our fiscal year earnings per share guidance on better than expected performance in our semiconductor business.

# Third quarter fiscal 2014 results vs. last year



(1), (2), (3), (4) & (5) See Footnotes page at the end of the presentation.

<sup>\*</sup> Q3'14 results included: \$208 million of income, or \$0.12 per share, of which \$184 million was recorded in other income, due to the reversal of accruals related to our litigation with ParkerVision; and \$164 million of charges, or \$0.08 per share, that resulted from an impairment on goodwill and long-lived assets related to our QMT (Qualcomm MEMS Technologies) division. Q3'13 results included: \$158 million charge, or \$0.06 per share, that resulted from an impairment on long-lived assets related to our QMT division.

# Third quarter fiscal 2014 results vs. guidance

|                                                                        | Q3'14 guidance*   | Q3'14 results |
|------------------------------------------------------------------------|-------------------|---------------|
| Revenues <sup>(1)</sup>                                                | \$6.2B - \$6.8B   | \$6.81B       |
| Non-GAAP <sup>(2)</sup> diluted EPS <sup>(3)**</sup>                   | \$1.15 - \$1.25   | \$1.44        |
| MSM chip shipments                                                     | 198M - 213M       | 225M          |
| Total reported device sales <sup>(4)</sup> (Mar. Qtr. <sup>(5)</sup> ) | \$56.0B - \$62.0B | \$58.1B       |
| Est. 3G/4G device shipments <sup>(4)</sup> (Mar. Qtr. <sup>(5)</sup> ) | not provided      | 250M - 254M   |
| Est. 3G/4G device ASP <sup>(4)</sup> (Mar. Qtr. <sup>(5)</sup> )       | not provided      | \$228 - \$234 |

<sup>\*</sup> Prior guidance as of Apr. 23, 2014.

<sup>\*\*</sup> Q3'14 results included: \$208 million of income, or \$0.12 per share, of which \$184 million was recorded in other income, due to the reversal of accruals related to our litigation with ParkerVision; and \$164 million of charges, or \$0.08 per share, that resulted from an impairment on goodwill and long-lived assets related to our QMT division.

<sup>(1), (2), (3), (4)</sup> & (5) See Footnotes page at the end of the presentation.

# Fiscal fourth quarter & year 2014 guidance


As of July 23, 2014

|                                                    | Q4'13<br>results | Q4'14<br>guidance | FY'13<br>results | FY'14 prior guidance* | FY'14 current guidance |
|----------------------------------------------------|------------------|-------------------|------------------|-----------------------|------------------------|
| Revenues <sup>(1)</sup>                            | \$6.48B          | \$6.5B - \$7.4B   | \$24.87B         | \$26.0B - \$27.5B     | \$26.3B - \$27.2B      |
| Non-GAAP <sup>(2)</sup> diluted EPS <sup>(3)</sup> | \$1.05           | \$1.20 - \$1.35   | \$4.51           | \$5.05 - \$5.25       | \$5.21 - \$5.36        |
| MSM chip shipments                                 | 190M             | 230M - 245M       | 716M             | not provided          | not provided           |
| Total reported device sales <sup>(4) (5)</sup>     | \$60.2B          | \$53.0B - \$59.0B | \$231.2B         | not provided          | not provided           |

<sup>\*</sup> Prior guidance as of Apr. 23, 2014. (1), (2), (3), (4) & (5) See Footnotes page at the end of the presentation.

## MSM chip shipments

#### Calendar year, millions




<sup>\*</sup> Guidance as of Jul. 23, 2014.

## Quarterly total reported device sales(4) (5)

#### Reported by Qualcomm licensees

- 260+ CDMA-based licensees; 185+ licensed for WCDMA/TD-SCDMA
- 110+ royalty-bearing single-mode OFDM/OFDMA licensees



<sup>(4) &</sup>amp; (5) See Footnotes page at the end of the presentation.

8


<sup>\*</sup> Guidance as of Jul. 23, 2014.

#### Estimated 3G/4G device shipments - update

- China continues to present significant opportunities for us, particularly with the rollout of 4G LTE, but also presents significant challenges, as our business practices continue to be the subject of an investigation by the China National Development and Reform Commission (NDRC).\*
- We also believe that certain licensees in China currently are not fully complying with their contractual obligations to report their sales of licensed products to us (which includes certain licensees underreporting a portion of their 3G/4G device sales and a dispute with a licensee) and that unlicensed companies may seek to delay execution of new licenses while the NDRC investigation is ongoing.
  - We expect calendar year 2014 3G/4G device shipments to be approximately 1.3 billion globally. However, our estimate of calendar year 2014 3G/4G device shipments that we currently expect to be reported to us is approximately 1.04 billion to 1.13 billion, which is adjusted for units that we believe may not be reported to us, are in dispute or are currently unlicensed.
  - We are taking steps to address these issues, although the timing of any resolution is uncertain.

# 3G/4G device shipment\* estimates<sup>(4)</sup>

Calendar year, millions, as of July 23, 2014



<sup>\*</sup> Device shipments are Qualcomm estimates and include handsets, data devices, telematics, security devices and some quantity of channel inventory.

<sup>\*\*</sup> We expect calendar year 2014 3G/4G device shipments to be approximately 1.3 billion globally. However, our estimate of calendar year 2014 3G/4G device shipments that we currently expect to be reported to us is approximately 1.04 billion to 1.13 billion, which is adjusted for units that we believe may not be reported to us, are in dispute or are currently unlicensed. We are taking steps to address these issues, although the timing of any resolution is uncertain.

(4) See Footnotes page at the end of the presentation.

## Quarterly estimated 3G/4G device shipments & ASP trend (4) (5)

|                                        |            | F۱         | <b>Y</b> '12 |            |            | F          | Y'13       |            |            |            | FY         | "14                    |
|----------------------------------------|------------|------------|--------------|------------|------------|------------|------------|------------|------------|------------|------------|------------------------|
|                                        | Sep<br>'11 | Dec<br>'11 | Mar<br>'12   | Jun<br>'12 | Sep<br>'12 | Dec<br>'12 | Mar<br>'13 | Jun<br>'13 | Sep<br>'13 | Dec<br>'13 | Mar<br>'14 | Jun<br>'14**           |
| Qtr. total reported device sales (\$B) | \$41.4     | \$51.7     | \$47.8       | \$46.5     | \$53.3     | \$61.1     | \$56.5     | \$60.2     | \$61.6     | \$66.5     | \$58.1     | \$53.0 - \$59.0e       |
| FY total reported device sales (\$B)   |            |            |              | \$187.3    |            |            |            | \$231.2    |            |            |            |                        |
| Qtr. device shipments* (M)             | 193        | 241        | 209          | 212        | 235        | 281        | 246        | 262        | 278        | 297        | 252        |                        |
| CY device shipments* (M)               |            | 795        |              |            |            | 937        |            |            |            | 1,083      |            | CY'14: 1,040 - 1,130e^ |
| FY device shipments* (M)               |            |            |              | 855        |            |            |            | 1,025      |            |            |            |                        |
| Qtr. device ASP*                       | \$215      | \$214      | \$229        | \$219      | \$227      | \$217      | \$230      | \$230      | \$222      | \$224      | \$231      |                        |
| FY device ASP*                         |            |            |              | \$219      |            |            |            | \$226      |            |            |            | \$222 - \$228e         |

(4) & (5) See Footnotes page at the end of the presentation.

Note: Sums of quarterly amounts may not equal totals due to rounding.


<sup>\*</sup> Midpoints, see note (6) on the Footnotes page at the end of the presentation.

<sup>\*\*</sup> Guidance as of Jul. 23, 2014.


<sup>^</sup> We expect calendar year 2014 3G/4G device shipments to be approximately 1.3 billion globally. However, our estimate of calendar year 2014 3G/4G device shipments that we currently expect to be reported to us is approximately 1.04 billion to 1.13 billion, which is adjusted for units that we believe may not be reported to us, are in dispute or are currently unlicensed. We are taking steps to address these issues, although the timing of any resolution is uncertain.

#### Cumulative \$31.1 billion returned to stockholders

As of June 29, 2014



\$6.5 billion remained available for repurchase under our stock repurchase program.



Note: The Company effected a two-for-one stock split in August 2004. All references to per share data have been adjusted to reflect the stock split.

<sup>\*</sup> Gross repurchases before commissions.

# Financial strength

| In billions                        | Jun'13 | Jun'14 |                                                            |
|------------------------------------|--------|--------|------------------------------------------------------------|
| Domestic                           | \$10.4 | \$6.9  |                                                            |
| Offshore                           | \$20.0 | \$25.8 | Cash resources and operating/ stock repurchase flexibility |
| Total cash & marketable securities | \$30.4 | \$32.7 |                                                            |
| Total assets                       | \$46.8 | \$48.4 |                                                            |
|                                    | ·      |        |                                                            |
| Stockholders' equity               | \$37.6 | \$38.8 | Solid balance sheet                                        |
| Debt*                              | \$0.0  | \$0.0  |                                                            |
| EBITDA**                           | \$2.0  | \$2.7  | Cash flow to support future                                |
| Free cash flow***                  | \$1.8  | \$2.5  | growth and dividends                                       |


<sup>\*</sup> Included capital leases.

<sup>\*\*</sup> EBITDA is defined as income from continuing operations before income tax expense, depreciation and amortization expense and interest and dividend income, net.

<sup>\*\*\*</sup> Free cash flow is defined as net cash provided by operating activities less capital expenditures.

#### Footnotes

- 1. Throughout this presentation, revenues, operating expenses, operating income, earnings before tax (EBT) and effective tax rates are from continuing operations (i.e., before adjustments for noncontrolling interests and discontinued operations), unless otherwise stated.
- 2. Non-GAAP results exclude the QSI (Qualcomm Strategic Initiatives) segment and certain share-based compensation, acquisition-related items and tax items.
- 3. Throughout this presentation, net income and diluted earnings per share (EPS) are attributable to Qualcomm (i.e., after adjustments for noncontrolling interests and discontinued operations), unless otherwise stated.
- 4. Total reported device sales is the sum of all reported sales in U.S. dollars (as reported to us by our licensees) of all licensed CDMA-based, OFDMA-based and CDMA/OFDMA multimode subscriber devices (including handsets, modules, modem cards and other subscriber devices) by our licensees during a particular period (collectively, 3G/4G devices). The reported quarterly estimated ranges of average selling prices (ASPs) and unit shipments are determined based on the information as reported to us by our licensees during the relevant period and our own estimates of the selling prices and unit shipments for licensees that do not provide such information. Not all licensees report sales, selling prices and/or unit shipments the same way (e.g., some licensees report sales net of permitted deductions, including transportation, insurance, packing costs and other items, while other licensees report sales and then identify the amount of permitted deductions in their reports), and the way in which licensees report such information may change from time to time. In addition, certain licensees may not report (in the quarter in which they are contractually obligated to report) their sales of certain types of subscriber units, which (as a result of audits, legal actions or for other reasons) may be reported in a subsequent quarter. Accordingly, total reported device sales, estimated unit shipments and estimated ASPs for a particular period may include prior period activity that was not reported by the licensee until such particular period.
- 5. Royalties are recognized when reported, generally one quarter following shipment.
- 6. The midpoints of the estimated ranges are identified for comparison purposes only and do not indicate a higher degree of confidence in the midpoints.



# Reconciliations

#### Non-GAAP results

#### In millions, except per share data

|                           | Non-GAAP |          | Share-Based      | Acquisition-      |           |         |
|---------------------------|----------|----------|------------------|-------------------|-----------|---------|
| SEGMENTS                  | (1)      | QSI (1)  | Compensation (1) | Related Items (1) | Tax Items | GAAP    |
| Q3 - FISCAL 2014          |          |          |                  |                   |           |         |
| Operating income (loss)   | \$2,425  | (\$5)    | (\$274)          | (\$71)            | \$ -      | \$2,075 |
| Change from prior year    | 19%      | 29%      | 2%               | -%                |           | 24%     |
| Income tax rate           | 13%      | -%       | 15%              | 7%                | N/A       | 10%     |
| Net income (loss)         | \$2,470  | \$ -     | (\$232)          | (\$66)            | \$66      | \$2,238 |
| Diluted EPS               | \$1.44   | \$0.00   | (\$0.14)         | (\$0.04)          | \$0.04    | \$1.31  |
| Change from prior year    | 40%      | N/M      | (8%)             | -%                | N/M       | 46%     |
| Change from prior quarter | 10%      | N/M      | (27%)            | 20%               | N/M       | 15%     |
| Diluted shares used       | 1,714    | 1,714    | 1,714            | 1,714             | 1,714     | 1,714   |
| Q2 - FISCAL 2014          |          |          |                  |                   |           |         |
| Net income (loss)         | \$2,255  | (\$17)   | (\$198)          | (\$81)            | \$ -      | 1,959   |
| Diluted EPS               | \$1.31   | (\$0.01) | (\$0.11)         | (\$0.05)          | \$ -      | \$1.14  |
| Diluted shares used       | 1,719    | 1,719    | 1,719            | 1,719             | 1,719     | 1,719   |
| Q3 - FISCAL 2013          |          |          |                  |                   |           |         |
| Operating income (loss)   | \$2,035  | (\$7)    | (\$280)          | (\$71)            | \$ -      | \$1,677 |
| Net income (loss)         | 1,823    | 43       | (222)            | (64)              | -         | 1,580   |
| Diluted EPS               | \$1.03   | \$0.02   | (\$0.13)         | (\$0.04)          | \$ -      | \$0.90  |
| Diluted shares used       | 1,765    | 1,765    | 1,765            | 1,765             | 1,765     | 1,765   |
| Q4 - FISCAL 2013          |          |          |                  |                   |           |         |
| Net income (loss)         | \$1,818  | (\$24)   | (\$226)          | (\$67)            | \$ -      | \$1,501 |
| Diluted EPS               | \$1.05   | (\$0.01) | (\$0.13)         | (\$0.04)          | \$ -      | \$0.86  |
| Diluted shares used       | 1,738    | 1,738    | 1,738            | 1,738             | 1,738     | 1,738   |
| 12 MONTHS - FISCAL 2013   |          |          |                  |                   |           |         |
| Net income (loss)         | \$7,911  | \$43     | (\$886)          | (\$279)           | \$64      | \$6,853 |
| Diluted EPS               | \$4.51   | \$0.02   | (\$0.51)         | (\$0.16)          | \$0.04    | \$3.91  |
| Diluted shares used       | 1,754    | 1,754    | 1,754            | 1,754             | 1,754     | 1,754   |

<sup>(1)</sup> At fiscal year end, the sum of the quarterly tax provision (benefit) for each column equals the annual tax provision (benefit) for each column computed in accordance with GAAP. In interim quarters, the sum of these provisions (benefits) may not equal the total GAAP tax provision, and this difference is allocated to tax provisions (benefits) among the columns.

N/A - Not Applicable

N/M - Not Meaningful

Sums may not equal totals due to rounding.

# Q3 FY'14 diluted EPS excluding specific items

|                                         | Diluted EPS |
|-----------------------------------------|-------------|
| Non-GAAP (1) - Excluding Specific Items | \$1.40      |
| ParkerVision reversal                   | \$0.12      |
| QMT impairment charges                  | (\$0.08)    |
| Non-GAAP (1) - As Reported              | \$1.44      |
| QSI                                     | \$0.00      |
| Share-based compensation                | (\$0.14)    |
| Acquisition-related items               | (\$0.04)    |
| Tax items                               | \$0.04      |
| GAAP                                    | \$1.31      |

<sup>(1)</sup> Non-GAAP results exclude the QSI segment and certain share-based compensation, acquisition-related items and tax items. Sum may not equal totals due to rounding.

# Q3 FY'14 combined R&D and SG&A expenses, sequential comparison

In millions

|                                             | •  | 2 FY14<br>esults | _•• | 3 FY14<br>esults | % Increase /<br>(Decrease) |
|---------------------------------------------|----|------------------|-----|------------------|----------------------------|
| Non-GAAP combined R&D and SG&A expenses (1) | \$ | 1,623            | \$  | 1,735            | 7%                         |
| QSI                                         |    | 6                |     | 5                | (17%)                      |
| Share-based compensation                    |    | 238              |     | 262              | 10%                        |
| Acquisition-related items                   |    | 28               |     | 9                | (68%)                      |
| Total GAAP combined R&D and SG&A expenses   | \$ | 1,895            | \$  | 2,011            | 6%                         |

<sup>(1)</sup> Non-GAAP combined R&D and SG&A expenses exclude expenses related to the QSI segment and certain share-based compensation and acquisition-related items.

#### EBITDA<sup>(1)</sup>

#### In millions

|                                             | Q3 FY13 |       | Q3 FY14 |       |
|---------------------------------------------|---------|-------|---------|-------|
|                                             |         |       |         |       |
| Income from continuing operations           | \$      | 1,578 | \$      | 2,237 |
| Plus: Income tax expense                    |         | 332   |         | 260   |
| Plus: Depreciation and amortization expense |         | 255   |         | 292   |
| Less: Interest and dividend income, net     |         | (175) |         | (139) |
| EBITDA                                      | \$      | 1,990 | \$      | 2,650 |

<sup>(1)</sup> EBITDA is defined as income from continuing operations before income tax expense, depreciation and amortization expense and interest and dividend income, net.

#### Free cash flow (a)

#### In millions

|                                                  | • •      |              |                     |          |
|--------------------------------------------------|----------|--------------|---------------------|----------|
|                                                  |          |              | Share-Based         |          |
|                                                  | Non-GAAP | QSI          | Compensation        | GAAP     |
| Net cash provided (used) by operating activities | \$ 2,752 | \$ (9)       | \$ (70) (b)         | \$ 2,673 |
| Less: capital expenditures                       | (158)    |              |                     | (158)    |
| Free cash flow                                   | \$ 2,594 | \$ (9)       | \$ (70)             | \$ 2,515 |
| Revenues                                         | \$ 6,806 | \$ -         | \$ -                | \$ 6,806 |
| Operating cash flow as % of revenues             | 40%      | N/A          | N/A                 | 39%      |
| Free cash flow as % of revenues                  | 38%      | N/A          | N/A                 | 37%      |
|                                                  | T        | ree Months E | Ended June 30, 2013 | }        |
|                                                  |          |              | Share-Based         | _        |
|                                                  | Non-GAAP | QSI          | Compensation        | GAAP     |
| Net cash provided (used) by operating activities | \$ 2,157 | \$ (5)       | \$ (75) (b)         | \$ 2,077 |
| Less: capital expenditures                       | (307)    | (7)          |                     | (314)    |
| Free cash flow                                   | \$ 1,850 | \$ (12)      | \$ (75)             | \$ 1,763 |
| Revenues                                         | \$ 6,243 | \$ -         | \$ -                | \$ 6,243 |
| Operating cash flow as % of revenues             | 35%      | N/A          | N/A                 | 33%      |
| Free cash flow as % of revenues                  | 30%      | N/A          | N/A                 | 28%      |
|                                                  |          |              |                     |          |

Three Months Ended June 29, 2014

N/A – Not Applicable

<sup>(</sup>a) Free cash flow is defined as net cash provided by operating activities less capital expenditures.

<sup>(</sup>b) Incremental tax benefits from share-based compensation during the period.

#### Business outlook

#### As of July 23, 2014

| FOURTH FISCAL QUARTER                                 | Q4 FY13  | Current Guidance    |
|-------------------------------------------------------|----------|---------------------|
| FOURTH FISCAL QUARTER                                 | Results  | Q4 FY14 Estimates   |
| Revenues                                              | \$6.48B  | \$6.5B - \$7.4B     |
| Year-over-year change                                 |          | even - increase 14% |
| Non-GAAP diluted EPS                                  | \$1.05   | \$1.20 - \$1.35     |
| Year-over-year change                                 |          | increase 14% - 29%  |
| Diluted EPS attributable to QSI                       | (\$0.01) | \$0.00              |
| Diluted EPS attributable to share-based compensation  | (\$0.13) | (\$0.13)            |
| Diluted EPS attributable to acquisition-related items | (\$0.04) | (\$0.04)            |
| GAAP diluted EPS                                      | \$0.86   | \$1.03 - \$1.18     |
| Year-over-year change                                 |          | increase 20% - 37%  |

| FISCAL YEAR                                           | FY 2013<br>Results | Prior Guidance<br>FY2014 Estimates (1) | Current Guidance<br>FY 2014 Estimates |
|-------------------------------------------------------|--------------------|----------------------------------------|---------------------------------------|
| Revenues                                              | \$24.87B           | \$26.0B - \$27.5B                      | \$26.3B - \$27.2B                     |
| Year-over-year change                                 |                    | increase 5% - 11%                      | increase 6% - 9%                      |
| Non-GAAP diluted EPS                                  | \$4.51             | \$5.05 - \$5.25                        | \$5.21 - \$5.36                       |
| Year-over-year change                                 |                    | increase 12% - 16%                     | increase 16% - 19%                    |
| Diluted EPS attributable to QSI                       | \$0.02             | (\$0.01)                               | (\$0.01)                              |
| Diluted EPS attributable to share-based compensation  | (\$0.51)           | (\$0.51)                               | (\$0.51)                              |
| Diluted EPS attributable to acquisition-related items | (\$0.16)           | (\$0.16)                               | (\$0.16)                              |
| Diluted EPS attributable to tax items                 | \$0.04             | N/A                                    | \$0.04                                |
| GAAP diluted EPS                                      | \$3.91             | \$4.37 - \$4.57                        | \$4.57 - \$4.72                       |
| Year-over-year change                                 |                    | increase 12% - 17%                     | increase 17% - 21%                    |

<sup>(1)</sup> Our prior guidance for fiscal 2014 GAAP diluted EPS excluded a \$66 million tax benefit that we recorded in the third quarter of fiscal 2014 as a result of an agreement reached with the Internal Revenue Service, which was excluded from our Non-GAAP results.

N/A - Not Applicable

Sums may not equal totals due to rounding.

# Q4 FY'14 combined R&D and SG&A expenses guidance

#### In millions

|                                                                                 | Q3 FY14<br>Results |       | Q4 FY14<br>Guidance* (est.)             |
|---------------------------------------------------------------------------------|--------------------|-------|-----------------------------------------|
| Non-GAAP combined R&D and SG&A expenses (1)                                     | \$                 | 1,735 | Decrease approx. 2% - flat sequentially |
| QSI                                                                             |                    | 5     | not provided                            |
| Acquisition-related items                                                       |                    | 9     | not provided                            |
| Total combined R&D and SG&A expenses excluding certain share-based compensation |                    | 1,749 | Decrease approx. 2% - flat sequentially |
| Share-based compensation allocated to R&D and SG&A                              |                    | 262   |                                         |
| Total GAAP combined R&D and SG&A expenses (2)                                   | \$                 | 2,011 | Decrease approx. 2% - flat sequentially |

<sup>(1)</sup> Non-GAAP combined R&D and SG&A expenses excludes expenses related to the QSI segment and certain acquisition-related items and share-based compensation.

<sup>(2)</sup> Q4 FY14 total GAAP combined R&D and SG&A expenses guidance includes an estimate of the share-based compensation expense allocated to R&D and SG&A.

<sup>\*</sup> Guidance as of Jul. 23, 2014

#### FY'14 combined R&D and SG&A expenses guidance

#### In millions

|                                                                                 | Fiscal 2013 Results |       | Fiscal 2014 Guidance* (est.) |
|---------------------------------------------------------------------------------|---------------------|-------|------------------------------|
| Non-GAAP combined R&D and SG&A expenses (1)                                     | \$                  | 6,393 | Increase approx. 5% - 6%     |
| QSI                                                                             |                     | 31    | not provided                 |
| Acquisition-related items                                                       |                     | 29    | not provided                 |
| Total combined R&D and SG&A expenses excluding certain share-based compensation |                     | 6,453 | Increase approx. 5% - 6%     |
| Share-based compensation allocated to R&D and SG&A                              |                     | 1,032 |                              |
| Total GAAP combined R&D and SG&A expenses (2)                                   | \$                  | 7,485 | Increase approx. 4% - 5%     |

<sup>(1)</sup> Non-GAAP combined R&D and SG&A expenses excludes expenses related to the QSI segment and certain acquisition-related items and share-based compensation.

<sup>(2)</sup> Fiscal 2014 total GAAP combined R&D and SG&A expenses guidance includes an estimate of the share-based compensation expense allocated to R&D and SG&A.

<sup>\*</sup> Guidance as of Jul. 23, 2014

# Thank you

Follow us on:



For more information on Qualcomm, visit us at: www.qualcomm.com & www.qualcomm.com/blog

©2014 Qualcomm Incorporated. All rights reserved. Qualcomm and MSM are trademarks of Qualcomm Incorporated, registered in the United States and in other countries.

